Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. (Q43056663)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20493771%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

title

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20493771%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20493771%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Giuseppe Giaccone

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20493771%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Emilio Esteban

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20493771%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

author name string

Tudor Ciuleanu

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20493771%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Lilia Stelmakh

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20493771%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Saulius Cicenas

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20493771%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Aleksandra Szczésna

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20493771%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Erzsébet Juhász

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20493771%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Olivier Molinier

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20493771%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Wolfram Brugger

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20493771%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Ivan Melezínek

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20493771%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Gaëlle Klingelschmitt

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20493771%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Barbara Klughammer

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20493771%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

SATURN investigators

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20493771%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

publication date

20 May 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20493771%20AND%20SRC:MED&resulttype=core&format=json

Lancet Oncology Commission

3 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20493771%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20493771%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20493771%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

page(s)

521-529

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20493771%20AND%20SRC:MED&resulttype=core&format=json

Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions.

3 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970112-1

7 January 2021

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970112-1

7 January 2021

Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970112-1

7 January 2021

Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970112-1

7 January 2021

Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970112-1

7 January 2021

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970112-1

7 January 2021

Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970112-1

7 January 2021

Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970112-1

7 January 2021

Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970112-1

7 January 2021

Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970112-1

7 January 2021

Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970112-1

7 January 2021

American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970112-1

7 January 2021

Multicenter, Randomized Trial for Stage IIIB or IV Non–Small-Cell Lung Cancer Using Weekly Paclitaxel and Carboplatin Followed by Maintenance Weekly Paclitaxel or Observation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970112-1

7 January 2021

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970112-1

7 January 2021

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970112-1

7 January 2021

Treatment paradigms for advanced stage non-small cell lung cancer in the era of multiple lines of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970112-1

7 January 2021

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970112-1

7 January 2021

American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970112-1

7 January 2021

Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970112-1

7 January 2021

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970112-1

7 January 2021

Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970112-1

7 January 2021

Salvage therapy for advanced non-small cell lung cancer: factors influencing treatment selection

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970112-1

7 January 2021

Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970112-1

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970112-1

7 January 2021

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970112-1

7 January 2021

10.1016/S1470-2045(10)70112-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20493771%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

1 reference